Compare Genuine Parts Company (GPC) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Humana Inc — how do they compare? Genuine Parts Company trades at $127.56 (market cap $17.67B), while Humana Inc trades at $451.1 (market cap $46.49B). The key difference: Humana Inc is far larger — about 2.6× Genuine Parts Company's market cap, and Genuine Parts Company pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Humana Inc for 53 Days on average.
| GPC | HUM | |
|---|---|---|
Market Cap | $17.67B | $46.49B |
Volume | 1,079,458 | 2,567,704 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $409.85 |
52-Week Low | $92.47 | $163.67 |
Typical Hold Time | 75 Days | 53 Days |
Enterprise Value | $23.76B | $53.84B |
Dividend Yield | 3.32% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.41, down 1.55% today, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 2026 results due October 20, 2026. Revenue grew to $24.3B in 2025, but net income margin fell sharply to 0.13%. Analyst consensus is a $145.75 price target with 43% buy ratings. Key developments include the planned spinoff of its industrial unit, Motion, in Q1 2027.
The outlook is cautious due to weak profitability and high P/E, but the spinoff could unlock value. Risks include execution challenges and economic sensitivity. Upside hinges on margin recovery and successful separation.
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
